免疫检查点抑制剂致免疫相关肝损伤的研究进展  

Research progress in immune-related liver injury caused by immune checkpoint inhibitors

作　　者：李凤惠[1] 王涛[1] 哈福双[1] 唐飞[1] 梁静[1] Li Fenghui;Wang Tao;Ha Fushuang;Tang Fei;Liang Jing(Department of Gastroenterology and Hepatology,The Third Central Hospital of Tianjin,Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases,Artificial Cell Engineering Technology Research Center,Tianjin Institute of Hepatobiliary Disease,Tianjin 300170,China)

机构地区：[1]天津市第三中心医院消化肝病科,天津市重症疾病体外生命支持重点实验室,天津市人工细胞工程技术研究中心,天津市肝胆疾病研究所,天津300170

出　　处：《国际生物医学工程杂志》2023年第2期169-174,共6页International Journal of Biomedical Engineering

基　　金：天津市医学重点学科(专科)建设项目(TJYXZDXK-034A)。

摘　　要：近年来,免疫检查点抑制剂(ICIs)在肿瘤患者的治疗中取得了很大进展,延长了患者的生存期。然而,在其增强免疫抗肿瘤的同时也可能造成免疫耐受失衡从而导致不同程度的免疫相关不良事件(irAEs)发生,ICIs致免疫相关肝损伤(ILICI)是其中较为常见的一种。主要对ILICI的定义、流行病学及危险因素、发病机制、病理及临床表现、治疗、复发及再治疗的研究进展进行综述。In recent years,immune checkpoint inhibitors(ICIs)have made great progress in the treatment of tumor patients,prolonging their survival.However,the expansion of immunity against tumors with ICIs may also cause an imbalance in immune tolerance,leading to immune-related adverse events(irAEs).Immune-mediated liver injury caused by ICIs(ILICI)is one of the more common types of irAEs.In this review paper,the definition,epidemiology,risk factors,pathogenesis,pathology,clinical manifestations,treatment,recurrence,and re-treatment of ILICI were summarized to provide a basis for clinical diagnosis and treatment.

关 键 词：免疫检查点抑制剂 免疫相关不良事件 免疫相关肝损伤 

分 类 号：R969.3[医药卫生—药理学]